Charles Schwab Investment Management Inc. boosted its position in shares of Charles River Laboratories International, Inc.

Bell Asset Management, an investment management company, released its Q4 2024 “Bell Global Equities Fund” investor letter. A ...

Smartleaf Asset Management LLC raised its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – ...

Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) is a leading provider of preclinical and clinical laboratory services for the pharmaceutical, biotechnology, and ...

Charles River Laboratories International, Inc. CRL reported fourth-quarter 2024 adjusted earnings per share (EPS) of $2.66, which rose 8.1% year over year. The figure surpassed the Zacks Consensus ...

Analysts on Wall Street project that Charles River Laboratories (CRL) will announce quarterly earnings of $2.50 per share in its forthcoming report, representing an increase of 1.6% year over year.

Redburn Atlantic upgraded Charles River (CRL) to Neutral from Sell with an $188 price target The firm says demand in the company’s Discovery ...

Charles River Labs (CRL) stock and LabCorp (LH) stock were upgraded and Quest Diagnostics (DGX) stock was downgraded at Citi.

Sign up for our free newsletters to receive the latest news from The Observer directly in your inbox.

The first test train has completed its first trip through the full length of the $5.5 billion City Rail Link - two months late.